Obesity in reproductive-aged women is associated with a shorter luteal phase and lower progesterone levels. Lipid accumulation in follicles of obese women compromises endoplasmic reticulum (ER) function, activating ER stress in granulosa cells. We hypothesized that ER stress activation in granulosa-lutein cells (GLCs) would modulate progesterone production and contribute to obesity-associated progesterone deficiency. Pretreatment with an ER stress inducer, tunicamycin or thapsigargin, inhibited human chorionic gonadotropin (hCG)-stimulated progesterone production in cultured human GLCs. Pretreatment of human GLCs with tunicamycin inhibited hCGstimulated expression of steroidogenic acute regulatory protein (StAR) and 3b-hydroxysteroid dehydrogenase (3b-HSD) messenger RNAs (mRNAs) without affecting expression of cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc), as determined by real-time quantitative polymerase chain reaction. Pretreatment with tunicamycin also inhibited hCG-stimulated expression of StAR protein and 3b-HSD enzyme activity in cultured human GLCs, as determined by Western blot analysis and an enzyme immunoassay, respectively, but did not affect hCG-induced intracellular 3',5'-cyclic adenosine monophosphate accumulation. Furthermore, tunicamycin attenuated hCGinduced protein kinase A and extracellular signal-regulated kinase activation, as determined by Western blot analysis. In vivo administration of tunicamycin to pregnant mare serum gonadotropin-treated immature mice prior to hCG treatment inhibited the hCG-stimulated increase in serum progesterone levels and hCG-induced expression of StAR and 3b-HSD mRNA in the ovary without affecting serum estradiol levels or the number of corpora lutea. Our findings indicate that ER stress in the follicles of obese women contributes to progesterone deficiency by inhibiting hCG-induced progesterone production in granulosa cells. (Endocrinology 158: 84-97, 2017) T he recent rapid increase in the obese population represents a serious health-care problem. Obesity is associated not only with metabolic and cardiovascular disease, but also with infertility. Obesity in women, independent of the presence of polycystic ovarian syndrome (PCOS), impairs reproduction by affecting menstrual cycle regularity and ovulatory function, as well as oocyte quality and the ovarian response to hormonal
Obesity in reproductive-aged women is associated with a shorter luteal phase and lower progesterone levels. Lipid accumulation in follicles of obese women compromises endoplasmic reticulum (ER) function, activating ER stress in granulosa cells. We hypothesized that ER stress activation in granulosa-lutein cells (GLCs) would modulate progesterone production and contribute to obesity-associated progesterone deficiency. Pretreatment with an ER stress inducer, tunicamycin or thapsigargin, inhibited human chorionic gonadotropin (hCG)-stimulated progesterone production in cultured human GLCs. Pretreatment of human GLCs with tunicamycin inhibited hCGstimulated expression of steroidogenic acute regulatory protein (StAR) and 3b-hydroxysteroid dehydrogenase (3b-HSD) messenger RNAs (mRNAs) without affecting expression of cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc), as determined by real-time quantitative polymerase chain reaction. Pretreatment with tunicamycin also inhibited hCG-stimulated expression of StAR protein and 3b-HSD enzyme activity in cultured human GLCs, as determined by Western blot analysis and an enzyme immunoassay, respectively, but did not affect hCG-induced intracellular 3',5'-cyclic adenosine monophosphate accumulation. Furthermore, tunicamycin attenuated hCGinduced protein kinase A and extracellular signal-regulated kinase activation, as determined by Western blot analysis. In vivo administration of tunicamycin to pregnant mare serum gonadotropin-treated immature mice prior to hCG treatment inhibited the hCG-stimulated increase in serum progesterone levels and hCG-induced expression of StAR and 3b-HSD mRNA in the ovary without affecting serum estradiol levels or the number of corpora lutea. Our findings indicate that ER stress in the follicles of obese women contributes to progesterone deficiency by inhibiting hCG-induced progesterone production in granulosa cells. (Endocrinology 158: [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] 2017) T he recent rapid increase in the obese population represents a serious health-care problem. Obesity is associated not only with metabolic and cardiovascular disease, but also with infertility. Obesity in women, independent of the presence of polycystic ovarian syndrome (PCOS), impairs reproduction by affecting menstrual cycle regularity and ovulatory function, as well as oocyte quality and the ovarian response to hormonal stimulation (1) . Even in normally cycling women, elevated body mass index is associated with a shorter luteal phase and lower progesterone levels (2, 3) .
The underlying mechanisms by which obesity impairs progesterone production are not fully elucidated. One possibility is that an alteration in luteinizing hormone (LH) pulsations induced by obesity diminishes progesterone production by the corpus luteum (2, 3) . Alternatively, adipokines such as leptin may affect granulosa-lutein cell (GLC) function, inhibiting progesterone production (4) (5) (6) . It is also possible that an altered follicular microenvironment in obese women might exert a detrimental effect on GLC function. Elevated body mass index is associated with elevated levels of triglycerides and free fatty acids in follicular fluid (7) (8) (9) . Accumulation of lipids in follicles of obese women or mice fed a high-fat diet activates endoplasmic reticulum (ER) stress in granulosa cells (9, 10) . ER stress, a condition in which unfolded or misfolded proteins accumulate in the ER as a result of an imbalance between the protein-folding load and capacity of the ER, is activated by various physiological and pathological conditions (11) . Exposure of the ER to high levels of free fatty acids and the resultant production of lipid peroxides compromise ER function, leading to the activation of ER stress (12) . ER stress in turn results in the activation of a group of transduction cascades that are collectively termed the unfolded protein response (UPR), which affect a wide variety of cellular functions (11) .
In previous studies, we demonstrated that ER stress in granulosa cells influences the regulation of cellular functions (13, 14) . We hypothesized that ER stress activated in GLCs of obese women modulates progesterone production and contributes to obesity-associated progesterone deficiency. To test this hypothesis, we investigated the effect of ER stress on progesterone production in cultured human GLCs in vitro, as well as in rodents in vivo. We also explored the underlying mechanism by which ER stress affects progesterone production in GLCs.
Materials and Methods

Animals
To examine the effects of obesity on ER stress activation in the ovary, 6-week-old female C57B6 Cg-Lep ob /J mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). Ob/Ob mice (Lep ob /Lep ob ; n = 5) with an average weight of 33.2 6 0.36 g and control mice (Lep ob /+; n = 5) with an average weight of 18.1 6 0.18 g were fed a normal diet. On day 15, mice were euthanized and ovaries were collected.
To address the effects of activation of ER stress on ovarian steroidogenesis, corpora lutea formation, and oocyte quality, immature female C57BL6/N mice were obtained from Japan SLC (Hamamatsu, Japan). Three-week-old female mice were divided into 2 groups: the control group received an intraperitoneal (IP) injection of 15 IU pregnant mare serum gonadotropin (PMSG; ASKA Pharmaceutical, Tokyo, Japan) on day 1, followed by IP injection of 15 IU human chorionic gonadotropin (hCG; Mochida Pharmaceutical, Tokyo, Japan) on day 3, and the tunicamycin treatment group received an IP injection with 1.0 mg tunicamycin (WAKO, Osaka, Japan) per gram of body weight on day 2, in addition to PMSG-hCG treatment as described for the control group. To examine the effects on ovarian steroidogenesis and corpora lutea formation, 4 mice from each group were euthanized 12, 24, or 48 hours after hCG injection, and ovaries and serum were collected. To examine the effects on oocyte quality, in vivo blastocyst formation was examined. All mice were mated with fertile males to induce pregnancy after 12 hours of hCG injection, and day 1 of pregnancy was defined as the day of vaginal plug formation. Four pregnant females from each group were euthanized on day 4 of pregnancy for the evaluation of blastocysts.
To examine the effects of tunicamycin and hCG separately, animals were treated as follows. hCG effects on ER stress activation in the ovary were examined in 3-week-old female mice divided into 2 groups: a control group (n = 4) that received an IP injection of 15 IU PMSG on day 1, followed by an IP injection of normal saline on day 3, and an hCG treatment group (n = 4) that received an IP injection of 15 IU hCG on day 3, in addition to PMSG treatment as described for the control group. Animals from each group were euthanized 12 hours after saline or hCG injection, and ovaries were collected. Tunicamycin effects on basal, but not hCG-induced, progesterone production, were examined in 3-weekold female mice divided into 2 groups: a control group (n = 12) that received an IP injection of 15 IU PMSG on day 1, followed by an IP injection of normal saline on day 3, and a tunicamycin treatment group (n = 12) that received an IP injection with 1.0 mg tunicamycin/g of body weight on day 2, in addition to PMSGsaline treatment as described for the control group. Four animals from each group were euthanized 12, 24, or 48 hours after saline injection, and serum were collected.
All experimental protocols were approved by the university's Committee on the Use and Care of Animals.
Isolation and culture of human GLCs
Follicular fluids with GLCs were aspirated from patients undergoing oocyte retrieval for in vitro fertilization at University of Tokyo Hospital and Matsumoto Ladies Clinic. All experimental procedures were approved by the institutional review boards, and signed informed consent was obtained from each patient. Isolation of GLCs was performed as reported previously (14) . Follicular fluids were centrifuged at 1500 m/s for 10 minutes, resuspended in phosphate-buffered saline with 0.2% hyaluronidase (Sigma-Aldrich, St. Louis, MO), and incubated at 37°C for 30 minutes. The suspension was layered over Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) and centrifuged at 700g for 30 minutes. GLCs were collected from the interphase and washed with phosphate-buffered saline. GLCs were cultured with Dulbecco's modified Eagle medium/F12 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS; BioWest, Nuaillé, France) and antibiotics (100 U/mL penicillin, 0.1 mg/mL streptomycin, and 250 ng/mL amphotericin B; Sigma-Aldrich) in 48-well, 12-well, or 6-well plates at a density of 2 3 10 5 cells/mL and allowed to adhere at 37°C in a humidified atmosphere containing 5% CO 2 . All GLCs press.endocrine.org/journal/endoused for this study were precultured for 3 to 5 days prior to treatment.
Treatment of human GLCs
To evaluate the effect of ER stress on hCG-stimulated progesterone production, GLCs were preincubated with an ER stress inducer, 2.5 mg/mL tunicamycin or 1 mM thapsigargin (Sigma-Aldrich) for 6 hours, followed by incubation with hCG (10 IU/mL) for 18 hours. To evaluate the effect of tunicamycin on hCG-or 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP)-stimulated messenger RNA (mRNA) expression of steroidogenesis-related genes, GLCs were preincubated with 2.5 mg/mL tunicamycin for 6 hours, followed by incubation with hCG (10 IU/mL) or 8-bromo-cAMP (1 mM) (SigmaAldrich) for 6 hours.
To evaluate the effect of tunicamycin on hCG-stimulated protein expression of steroidogenic acute regulatory protein (StAR) or hCGstimulated 3b-hydroxysteroid dehydrogenase (3b-HSD) activity, GLCs were preincubated with 2.5 mg/mL tunicamycin for 6 hours, followed by incubation with 10 IU/mL hCG for 18 hours. To assess 3b-HSD activity, GLCs were incubated with 5 mg/mL pregnenolone (Sigma-Aldrich), a substrate of 3b-HSD, and aminoglutethimide (20 mm) (Sigma-Aldrich) after preincubation with tunicamycin and hCG. Because aminoglutethimide inhibits cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc)-mediated hydroxylation of cholesterol, addition of this compound along with pregnenolone enables progesterone production to serve as an index of 3b-HSD activity (15) .
To evaluate the effect of tunicamycin on hCG-stimulated intracellular cAMP accumulation and on the hCG-stimulated increase in the phosphorylation of protein kinase A (PKA) substrates, GLCs were preincubated with 2.5 mg/mL tunicamycin for 6 hours, followed by incubation with 10 IU/mL hCG for 60 minutes. To evaluate the effect of tunicamycin on hCG-stimulated phosphorylated extracellular signal-regulated kinase (ERK) 1 and ERK2 protein expression, GLCs were preincubated with 2.5 mg/mL tunicamycin for 6 hours, followed by incubation with 10 IU/mL hCG for 10 minutes.
RNA extraction, real-time polymerase chain reaction, and quantitative real-time polymerase chain reaction Total RNA was extracted from mouse ovaries using ISOGEN (NIPPON GENE, Tokyo, Japan). One microgram of total RNA was reverse transcribed in a 40-mL volume using the ReverTra Ace qPCR RT Master Mix with genomic DNA remover (TOYOBO, Osaka, Japan). Synthesis of complementary DNA templates from human GLCs was performed using the SuperPrep Cell Lysis and RT Kit for qPCR (TOYOBO). To quantitate mRNA levels, real-time polymerase chain reaction (PCR) was performed on a Light Cycler (Roche Diagnostic, Mannheim, Germany). StAR, P450scc, 3b-HSD, and aromatase were examined as steroidogenesis-related genes. For human GLCs, the expression of LH/hCG receptor (LHR) was also examined. The UPR genes, the spliced form of X-box-binding protein 1 [XBP1(S)], activating transcription factor 4 (ATF4), ATF6, and heat shock 70kDa protein 5 (HSPA 5) were examined as markers of ER stress activation. Expression levels were normalized against the corresponding level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, used as an internal standard for RNA loading. Primer sequences were as follows: human XBP1(S) (sense, 5
0 -AACCCCATGCAGTATAATGTCAC-3 0 ; antisense, 5 0 -AGGACCTGGTATTGAAGACGAG-3), and mouse GAPDH (sense, 5 0 -AGGTCGGTGTGAACGGATTTG-3 0 ; antisense, 5 0 -TGTAGACCATGTAGTTGAGGTCA-3 0 ). PCR conditions were as follows: for human aromatase, human LHR, human GAPDH, mouse XBP1(S), mouse ATF4, mouse ATF6, mouse HSPA5, mouse StAR, mouse P450scc, mouse 3b-HSD, mouse aromatase, and mouse GAPDH, 40 cycles at 98°C for 10 seconds, 60°C for 10 seconds, and 68°C for 30 seconds; for human P450scc and human 3b-HSD, 40 cycles at 98°C for 10 seconds, 62°C for 10 seconds, and 68°C for 30 seconds; for human XBP1(S) and human StAR, 40 cycles at 98°C for 10 seconds, 66°C for 10 seconds, and 68°C for 30 seconds. All samples of GLCs and mice ovaries were analyzed in triplicate or quadruplicate.
Progesterone assays
Concentrations of human progesterone in cell culture supernatants and mouse progesterone in serum were measured using the Progesterone enzyme immunoassay (EIA) kit (Cayman Chemical, Minneapolis, MN). Absorbance was read at 420 nm on an Epoch multivolume spectrophotometer system (BioTek, Winooski, VT). The sensitivity limit of the assay was 10 pg/mL. Cell culture samples were analyzed in sextuplicate.
Western blot analysis
GLCs were lysed in lysis buffer (Cell Signaling Technology, Danvers, MA) containing phosphatase inhibitors (Nacalai Tesque, Kyoto, Japan) and protease inhibitors (Roche Diagnostic), and insoluble material was removed by centrifugation at 14,000 m/s for 12 minutes at 4°C. The supernatants were recovered, and the protein concentrations were measured using Bio-Rad protein assay reagent (Bio-Rad Laboratory, Hercules, CA). Equivalent amounts of lysate protein (10 mg) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically transferred onto polyvinylidene difluoride membranes (GE Healthcare) using Direct Blot (SHARP, Osaka, Japan). Membranes were probed with primary and secondary antibody using the iBind Flex Western System (GE Healthcare). Primary antibodies were used at the following concentrations: anti-StAR (Santa Cruz Biotechnology, Dallas, TX), 1:200; antiphospho-PKA substrate (RRXS*/T*) (Cell Signaling Technology), 1:500; antiphospho-ERK1/2 (Cell Signaling Technology), 1:500; anti-ERK1/2 (Cell Signaling Technology), 1:500; and b-Actin (Santa Cruz Biotechnology), 1:200. The primary antibodies are listed in Table 1 . Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit or anti-goat, 1:1000, Jackson ImmunoResearch Laboratories, West Grove, PA) and ECL Prime Western Blotting Detection Reagent (GE Healthcare) were used for chemiluminescence detection. The images were acquired on a C-Digit instrument (LI-COR, Lincoln, NE).
Intracellular cAMP accumulation assay
Intracellular cAMP accumulation in human GLCs was measured using a cAMP Select enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical). Absorbance was read at 420 nm on an Epoch multivolume spectrophotometer system (BioTek). The sensitivity limit of the assay was 0.6 pmol/mL. Cell culture samples were analyzed in quintuplicate.
Estradiol assays
Concentration of mouse estradiol in serum was measured using the Rodent Estradiol ELISA test kit (Endocrine Technologies, Newark, CA). Absorbance was read at 450 nm on an Epoch multivolume spectrophotometer system (BioTek). The sensitivity limit of the assay was 5 pg/mL.
Histology
Ovaries were fixed in 10% natural buffered formalin, embedded in paraffin, and sectioned at a thickness of 3 mm. Sections were stained with hematoxylin and eosin, and corpora lutea were counted in the largest-diameter section of each ovary.
Statistical analysis
Statistical analyses were performed using the JMP Pro 11 software (SAS Institute, Cary, NC). All results are shown as mean 6 standard error of the mean. Data were analyzed using Student t test for paired comparison, and the Tukey-Kramer honest significant difference for multiple comparisons. A P value , 0.05 was considered significant.
Results
ER stress is activated in the ovary of obese mice
To confirm the activation of ER stress in the ovary of obese individuals, mRNA expression levels of UPR genes in the ovary of Ob/Ob mice were compared with those of control lean mice. Because the metazoan UPR consists of 3 branches, we examined the expression of UPR genes in each branch, namely XBP1(S), ATF4, and ATF6. In addition, we also examined the expression of HSPA5, a major UPR gene which acts as an ER chaperone to help folding proteins. All of these UPR genes were upregulated in the ovaries of obese mice, suggesting that ER stress is activated in the ovaries of these mice (Fig. 1) . Hereafter, only XBP1(S) was examined as a marker of ER stress activation.
Tunicamycin and thapsigargin inhibit hCGstimulated progesterone secretion in human GLCs
Pretreatment with the ER stress inducer tunicamycin decreased hCG-stimulated progesterone secretion in GLCs to almost the same level as in unstimulated GLCs [ Fig. 2(A) ]. For further confirmation, we examined the effect of pretreatment with thapsigargin, another ER stress inducer, and obtained similar results [ Fig. 2(B) ]. Tunicamycin inhibits hCG-stimulated StAR and 3b-HSD mRNA expression in human GLCs without affecting P450scc, aromatase, or LHR mRNA expression To elucidate the underlying mechanism via which ER stress interferes with progesterone production, we examined the effect of tunicamycin on the mRNA expression of hCG-stimulated steroidogenesis-related genes in human GLCs. hCG increased the expression levels of StAR, P450scc, 3b-HSD, and aromatase mRNAs. Pretreatment with tunicamycin inhibited hCG-stimulated StAR and 3b-HSD mRNA expression without affecting the levels of P450scc or aromatase mRNA [ Fig. 3(A-D) ]. In addition, pretreatment with tunicamycin did not affect hCG-induced LHR mRNA expression [ Fig. 3(E) ]. Induction of ER stress by tunicamycin increased the expression levels of XBP1(S) mRNA [ Fig. 3(F) ], confirming that ER stress was activated in these cells. Interestingly, hCG itself induced a slight increase in XBP1(S) mRNA (2.3-fold compared with the control), and when it was administered with tunicamycin, it had a synergistic effect on XBP1(S) induction.
Tunicamycin inhibits hCG-stimulated expression of StAR protein and 3b-HSD enzyme activity in human GLCs
Next, we determined the effect of tunicamycin on hCGstimulated expression of StAR protein and 3b-HSD enzyme activity. Western blot analysis was performed using anti-StAR antibody to examine StAR protein expression. To assess 3b-HSD enzyme activity, GLCs were incubated with pregnenolone and aminoglutethimide after preincubation with tunicamycin and hCG. Pregnenolone is a substrate for 3b-HSD, and aminoglutethimide inhibits production of pregnenolone from cholesterol. Therefore, addition of aminoglutethimide along with pregnenolone enables progesterone production to serve as an index of 3b-HSD activity (15) . hCG increased both expression of StAR protein and 3b-HSD enzyme activity. Both hCG-stimulated expression of StAR protein and 3b-HSD enzyme activity were downregulated by pretreatment with tunicamycin [ Fig. 4(A) and 4(B) ].
Tunicamycin interferes with PKA-and ERKstimulated steroidogenesis in human GLCs
Next, we investigated the site of action of tunicamycin. When LH/hCG binds to the LHR on GLCs, adenylyl cyclase is activated, increasing intracellular cAMP; this in turn results in PKA and ERK1/2 activation, which then activates the downstream steroidogenic pathway.
First, we examined the effect of tunicamycin on hCGstimulated intracellular cAMP accumulation. As shown in Fig. 5(A) , tunicamycin treatment did not affect hCGstimulated intracellular cAMP accumulation. Next, we examined the effect of tunicamycin on mRNA expression of the cAMP-stimulated steroidogenesis-related genes StAR, pP450scc, 3b-HSD, and aromatase. Consistent with the results obtained using hCG, tunicamycin treatment inhibited cAMP-stimulated expression levels of StAR and 3b-HSD mRNAs without affecting the levels of P450scc or aromatase mRNA [ Fig. 5(B-E) ]. Induction of ER stress by tunicamycin was confirmed by elevated expression of XBP1(S) mRNA [ Fig. 5(F) ].
Given that tunicamycin does not affect hCG-stimulated intracellular cAMP accumulation but affects the expression of hCG-and cAMP-stimulated progesterone biosynthesisrelated genes in the same way, the inhibitory effects of tunicamycin may be exerted downstream of adenylyl cyclase (16) . To test this hypothesis, we examined the effects of tunicamycin on activation of PKA by Western blotting, using an antibody directed against PKA consensus phosphorylation sites (RRXS*/T*) (17) . As shown in Fig. 5(G) , pretreatment with tunicamycin inhibited the hCG-induced increase in the phosphorylation of PKA substrates. We also examined the effects of tunicamycin on activation of ERK1/2 by Western blotting, using an antibody directed against phospho-ERK1/2. As shown in Fig. 5 (H), pretreatment with tunicamycin inhibited hCG-induced phosphorylation of ERK1/2.
Tunicamycin inhibits hCG-stimulated progesterone production in mice, inhibiting hCG-stimulated StAR and 3b-HSD mRNA expression in the ovary Next, we examined the in vivo effect of activation of ER stress on progesterone production. Administration of tunicamycin to PMSG-treated immature mice increased mRNA expression of the ER stress marker XBP1(S) in the ovary [ Fig. 6(A) ], demonstrating that ER stress was activated in this tissue. When ER stress was activated, hCG-stimulated progesterone production was inhibited after 48 hours of hCG treatment, at a time when progesterone production should reach its maximum level [ Fig. 6(B) ]. Tunicamycin treatment did not affect estradiol production or the number of corpora lutea [ Fig. 3(A-D) ]. As regards oocyte quality, the blastocyst development rate was not affected by administration of tunicamycin [ Fig. 6(I) ]. As shown in Supplemental Fig. 1(A) , hCG itself induced a slight increase in XBP1(S) expression, which is in accordance with the results obtained with human cultured GLCs [ Fig. 3(F) ]. Supplemental Fig. 1(B) shows that treatment with tunicamycin did not affect the basal progesterone production, which is in accordance with the results obtained with human cultured GLCs [ Fig. 2(A) ].
Discussion
Our results show that ER stress was activated in the ovaries of obese mice, and pretreatment with an ER stress Figure 2 . Effect of the ER stress inducers tunicamycin (Tm) and thapsigargin (Tg) on hCG-stimulated progesterone secretion in human GLCs. Human GLCs were preincubated with (A) 2.5 mg/mL Tm or (B) 1 mM Tg for 6 hours, followed by incubation with hCG (10 IU/mL) for 18 hours. Progesterone levels in culture supernatants were measured using EIA. Data represent means 6 standard errors of the mean of sextuplicate trials, and the results shown are representative of at least 3 replicate experiments from 3 different samples. Letters denote significant differences between groups (P , 0.05). doi: 10.1210/en.2016-1511 press.endocrine.org/journal/endoinducer inhibited hCG-stimulated progesterone production in granulosa cells both in vitro and in vivo. ER stress inhibited hCG-stimulated expression and enzyme activity of progesterone biosynthesis-related genes, specifically, mRNA and protein expression of StAR, as well as mRNA expression and enzyme activity of 3b-HSD. Activation of ER stress attenuated the hCG-induced increase in the phosphorylation of PKA substrates and ERK1/2 without affecting hCG-stimulated intracellular cAMP accumulation (Fig. 7) . In the ovaries of obese mice, the expression of the UPR genes, XBP1(S), ATF4, ATF6, and HSPA5 was upregulated. The UPR is a group of transduction cascades activated by ER stress (11) . Accordingly, increases in the expression of UPR genes indicate the activation of ER stress in the ovaries of obese mice, which is consistent with results of another recent article (10) .
Pretreatment with an ER stress inducer inhibited hCGstimulated, but not basal, progesterone production in human GLCs and in PMSG-hCG-treated immature mice. Treatment of human GLCs or mice with an ER stress inducer before hCG treatment mimicked the situation in follicles in obese women, in which ER stress is activated prior to entry into luteal phase. Administration of an ER stress inducer to PMSG-hCG-treated immature mice affected neither serum estradiol concentration nor the number of corpora lutea, which indicated that follicular growth, ovulation, and corpus luteum formation were not affected by ER stress in the ovary. These findings suggest that ER stress in the ovary impairs the hCGstimulated steroidogenic function of granulosa cells, even in normal ovulatory cycles.
In the current study, we examined the underlying mechanisms by which ER stress impairs progesterone production in granulosa cells. ER stress inhibited hCGstimulated mRNA and protein expression of StAR, as well as mRNA expression and enzyme activity of 3b-HSD, in human GLCs. In addition, ER stress inhibited hCG-stimulated mRNA expression of StAR and 3b-HSD in the ovaries of PMSG-hCG-treated immature mice. In a time-course study conducted with mice, ER stress was already activated in the ovaries 12 hours after hCG injection, whereas it took 48 hours after hCG injection to decrease the serum progesterone level. Progesterone production is predicted to reach its maximum value at 48 hours after hCG injection. When we examined the chronological induction of StAR and 3b-HSD mRNA by hCG alone, StAR expression had already reached its maximum level 12 hours after hCG injection, whereas 3b-HSD did not achieve its maximum level until 48 hours after hCG injection. StAR is the rate-limiting de novo protein in progesterone synthesis, and 3b-HSD is the ERresident enzyme that catalyzes the formation of progesterone from pregnenolone. Our results show that tunicamycin injection inhibited hCG-induced StAR mRNA expression 12 hours after hCG treatment, whereas it inhibited hCG-induced 3b-HSD mRNA expression 48 hours after hCG treatment. XBP1(S), induced by ER stress, works as a transcription factor to regulate the expression of various genes to allow cells to cope with ER stress and to restore homeostasis (11) . Accordingly, it is conceivable that XBP1(S) activation precedes the inhibition of mRNA expression of StAR and 3b-HSD, resulting in the inhibition of progesterone production. It is plausible that ER stress interferes in several of the steps leading to hCG-induced progesterone production, such as during the induction of StAR and 3b-HSD.
Several studies have reported the association between activation of ER stress and inhibition of steroid biosynthesis-related genes in rodent gonads. As for the ovary, in vitro examination of mouse primary granulosa cells revealed that activation of ER stress inhibits FSHstimulated aromatase mRNA expression, decreasing estrogen production (18) . Another in vivo study showed that treatment of rats with an ER stress inducer in midluteal phase decreases serum progesterone level and the expression of StAR and 3b-HSD proteins in corpora lutea (19) . In male gonads, in vitro examination with mouse Leydig tumor cell lines revealed that ER stress inhibits hCG-stimulated StAR, P450scc, and 3b-HSD mRNA expression, decreasing progesterone production (20, 21) . Other in vivo studies demonstrated an association between ER stress and steroidogenesis in testes. For example, in the testes of type 2 diabetic model rats, ER stress is activated and inhibits StAR mRNA expression (22) . In addition, ER stress activated by hypoxia or hyperthermia decreases the expression of StAR and 3b-HSD in testes, with a concomitant reduction in serum testosterone levels (21, 23, 24) . Thus, it is plausible that steroidogenesis in gonads is modulated by local ER stress. Moreover, our results show that hCG itself induced a slight increase in XBP1(S) mRNA expression, and coadministration of hCG and tunicamycin exerted a synergistic effect on XBP1(S) mRNA expression both in in vivo and in vitro. This is in contrast to the suppressive effects of FSH on XBP1(S) expression reported in a recent article (18) , in which it was shown that FSH decreases XBP1(S) mRNA expression but does not affect the tunicamycin-induced increase in XBP1(S) mRNA. The interrelationship between ER stress and gonadotropins is complicated, which indicates that these factors probably need to be fine-tuned for appropriate steroidogenesis in granulosa cells. . by incubation with 10 IU/mL hCG for 60 minutes. Western blot analysis was performed using antiphospho-PKA substrate antibody, an antibody directed against PKA consensus phosphorylation sites (RRXS*/T*); b-actin was used as a loading control. (H) Human GLCs were preincubated with 2.5 mg/mL Tm for 6 hours, followed by incubation with 10 IU/mL hCG for 10 minutes. Western blot analysis was performed using anti-ERK1/2 and antiphospho ERK1/2 antibodies. Results shown are representative of at least 3 replicate experiments from 3 different samples. Letters denote significant differences between groups (P , 0.05). press.endocrine.org/journal/endo
Our results show that ER stress inhibited hCG-and cAMP-stimulated progesterone biosynthesis-related genes in the same way, without affecting hCG-stimulated intracellular cAMP accumulation, and inhibited the hCG-stimulated increase in the phosphorylation of PKA substrates. These findings indicate that ER stress interferes with cAMP/PKA-stimulated steroidogenic pathways at a step downstream of adenylate cyclase in human granulosa cells. Upon binding of the ligand, the LHR predominantly activates adenylyl cyclase to increase the cAMP level, thereby activating PKA. Activation of ERK and epidermal growth factor receptor signaling by PKA are necessary to induce expression of genes essential for progesterone production (25, 26) . In our present study, ER stress inhibited the hCG-stimulated increase in the phosphorylation of ERK1/2. Of note, activation of ERK occurs in both PKA-dependent and PKA-independent manners (27) . Our results show that treatment with tunicamycin inhibited hCG-induced ERK1/2 phosphorylation as early as 10 minutes after hCG treatment, whereas inhibition of PKA activation was most prominent after 60 minutes of hCG treatment. These results indicate that ER stress might interfere with another pathway such as PKA-independent ERK activation, in addition to cAMP/PKA-stimulated steroidogenic pathways. LH signaling also activates another PKA-independent signaling, the phospholipase C/ inositol triphosphate 3/Ca 2+ pathway, which might also be involved in LH-stimulated progesterone production via activation of calmodulin-dependent kinase (28, 29) . The mechanism regulating the expression of genes essential for progesterone production is not yet fully elucidated. Recent studies unveiled the involvement of signaling pathways other than cAMP/PKA (30, 31) . Future studies will be required to determine whether ER stress affects LH/hCG-mediated signaling outside the well-studied cAMP/PKA pathways.
Of note, we previously reported that hCG-induced expression of vascular endothelial growth factor A (VEGFA) was upregulated by ER stress (14) , whereas in this study, we report that the expression of hCGstimulated progesterone biosynthesis-related genes, StAR and 3b-HSD, is inhibited by ER stress. ER stress may have conflicting effects downstream of LH/hCG stimulation. Before discussing these conflicting effects, it is important to emphasize that both of the underlying mechanisms via which hCG induces the expression of VEGFA expression and progesterone biosynthesisrelated genes have not been fully elucidated and are likely complicated. Given the uncertainty about the regulatory mechanisms that govern the effect of hCG on these genes, it is plausible that ER stress affects the expression of VEGFA differently from the way it affects the expression of progesterone biosynthesis-related genes. One possible explanation for the difference between the effect of ER stress on hCG-induced VEGFA expression and progesterone biosynthesis-related genes is that the former is, at least partly, a result of direct transcriptional regulation, whereas the latter is not. The VEGFA promoter region harbors a number of potential binding sites for XBP1 (S), a transcription factor induced by ER stress. On the other hand, none of the progesterone biosynthesisrelated genes, StAR, P450scc, or 3b-HSD, harbor potential binding sites for XBP1(S) in their promoter regions. In fact, activation of ER stress itself, even without hCG treatment, increases VEGFA expression (14) , whereas it has no effect on StAR or 3b-HSD expression. Another possible explanation is that the mechanism via which hCG induces VEGFA may involve local products of hCG action in target cells, such as insulin-like growth factors, as well as nonendocrine factors, such as hypoxia (32) . ER stress may stimulate VEGFA expression by increasing the expression/activity of local factors rather than by employing the direct pathway from hCG to VEGFA expression. Research on ER stress in the ovary is still in its infancy. Future studies will be required to elucidate the regulatory role of ER stress in ovarian function, as well as the interrelationship between the roles of ER stress and gonadotropins.
Our findings indicate that ER stress in the follicles of obese women inhibits hCG-stimulated progesterone production in granulosa cells. However, ER stress activated by locally accumulating lipids is not the only adverse effect of obesity on the follicular microenvironment. In addition, oxidative stress and inflammation are observed in the follicles of obese women. High levels of intracellular free fatty acids impair mitochondrial membrane structure, as well as ER function, causing release of reactive oxygen species (33) . The levels of oxidative stress markers in the follicular fluid of obese women are elevated irrespective of the presence of PCOS (34, 35) . Chronic, low-grade inflammation is a common phenotype of obesity. Recent studies showed that obesity is associated with local ovarian inflammation, as well as systemic inflammation. The levels of C-reactive protein and inflammatory cytokines such as interleukin 6 and tumor necrosis factor a are elevated in the follicular fluid of obese women (7, 36) . Investigation of a rodent model revealed that progressive obesity affects ovarian proinflammatory signaling (37) . Furthermore, obesity is associated with elevated permeability of the gut epithelium as a result of alteration in gut microbial populations, as well as ovarian inflammation (38, 39) . Both oxidative stress and inflammation inhibit progesterone production in the ovary (39) (40) (41) (42) (43) (44) (45) . ER stress is induced by a broad spectrum of conditions that increase the demand for protein folding or disrupt protein-folding reactions in the ER; these include oxidative stress and inflammation, as well as lipotoxicity (46, 47) . In turn, ER stress induces oxidative stress and inflammation (inflammation is also induced by oxidative stress) (47) (48) (49) (50) . It is plausible that ER stress, oxidative stress, and inflammation in the follicular microenvironment cooperatively interfere with progesterone production in the follicles of obese women.
In addition to progesterone production, we also examined the effects of ER stress activation by tunicamycin on blastocyst formation, given that oocyte quality is known to be impaired in obese women (1) . The results showed that blastocyst development rate was not affected by ER stress activation. However, this does not exclude the possibility that activation of ER stress impairs blastocyst development, because we cannot exclude the possibility that other doses or frequencies of tunicamycin injection will have an effect on blastocyst formation. Future investigations will be required to determine whether ER stress activation in the ovaries of obese women affects oocyte quality and development capacity.
In summary, we demonstrated that ER stress in granulosa cells inhibits hCG-stimulated expression and activity of progesterone synthesis-related genes and decreases progesterone production by affecting PKA and ERK activation. Our findings suggest that ER stress in the follicles of obese women contributes to progesterone deficiency by inhibiting hCG-induced progesterone production in granulosa cells. press.endocrine.org/journal/endo
